Scarica l'app Stockscreener
8.51
0.35%
0.03
Dopo l'orario di chiusura:
8.51
Precedente Chiudi:
$8.48
Aprire:
$8.3
Volume 24 ore:
25,998
Relative Volume:
0.69
Capitalizzazione di mercato:
$49.21M
Reddito:
$43.77M
Utile/perdita netta:
$-35.04M
Rapporto P/E:
-2.6168
EPS:
-3.2521
Flusso di cassa netto:
$-5.51M
1 W Prestazione:
-1.96%
1M Prestazione:
+12.40%
6M Prestazione:
-24.02%
1 anno Prestazione:
-16.87%
Intervallo 1D:
$8.20
$8.57
Intervallo di 1 settimana:
$8.0201
$8.88
Portata 52W:
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.51 | 49.21M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Surprises Report: How cyclical is Xilio Therapeutics Incs revenue streamQuarterly Investment Review & Real-Time Stock Entry Alerts - baoquankhu1.vn
XLO Should I Buy - Intellectia AI
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Xilio Therapeutics Announces Inducement Grants - National Today
Xilio Therapeutics Grants Inducement Shares Under Nasdaq Rule - National Today
Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan
Xilio Therapeutics, Inc. (XLO) stock price, news, quote and history - Yahoo Finance UK
XLO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Xilio Therapeutics (XLO) Raised to Buy: How Will This Impact the Shares? - Bitget
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Update Report: Does Xilio Therapeutics Inc have high return on assets2026 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
Retail Trends: Can Xilio Therapeutics Inc deliver alphaMarket Sentiment Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares - Investing.com
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares By Investing.com - Investing.com India
Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy - MarketBeat
Retail Trends: Can Xilio Therapeutics Inc expand into new marketsWeekly Stock Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Market Catalysts: How much upside does Xilio Therapeutics Inc have2026 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Xilio plans mid-2026 IND filing for cancer therapy XTX501 By Investing.com - Investing.com Australia
Xilio Therapeutics Extends Cash Runway Through 2027 and Advances Masked Immuno-Oncology Pipeline, Including XTX501 and Multi-Specific T Cell Engagers 123 - minichart.com.sg
Xilio Therapeutics: Advancing Masked Immuno-Oncology Therapies for Improved Cancer Outcomes - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xilio plans mid-2026 IND filing for cancer therapy XTX501 - Investing.com
Xilio Therapeutics 2025 10-K: Revenue $43.8M, EPS (loss) $0.00 - TradingView
Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan
XLO: Collaboration revenue surged and cash runway extended as pipeline advanced toward key milestones - TradingView
Xilio (NASDAQ: XLO) boosts 2025 revenue and cash runway into 2027 - Stock Titan
BRIEF-Xilio Therapeutics Q4 Net Income USD 10.36 Million - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Xilio Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan
Volume Summary: Can Xilio Therapeutics Inc deliver alphaWeekly Stock Summary & Daily Entry Point Alerts - baoquankhu1.vn
Trading Recap: What is the long term forecast for Xilio Therapeutics Inc stockGold Moves & Community Consensus Picks - baoquankhu1.vn
Can Xilio Therapeutics Inc sustain earnings growthWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Exit Recap: Will Boyd Gaming Corporation stock benefit from M A2026 EndofMonth & Weekly Return Optimization Plans - baoquankhu1.vn
XLO Forecast, Price Target & Analyst Ratings | XILIO THERAPEUTICS INC (NASDAQ:XLO) - ChartMill
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com Australia
Xilio Therapeutics to present data on masked cancer therapy at AACR By Investing.com - Investing.com South Africa
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - marketbeat.com
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Bitget
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com Canada
Xilio Therapeutics announces 1-for-14 reverse stock split - MSN
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - Sahm
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):